Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
FRIEDLANDS 10.000-JAHRE-SCHOCK: Der Kupfer-Engpass hat begonnen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
127 Leser
Artikel bewerten:
(0)

China In-vitro Diagnostic Reagent Industry Report 2017-2021 - Research and Markets

DUBLIN, Apr. 21, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Research Report on China In-vitro Diagnostic Reagent Industry, 2017-2021" report to their offering.

Research and Markets Logo

The market size of China in-vitro diagnostic reagents reached about CNY 26 billion (USD 3.9 billion) in 2016, of which the leading three were immune, biochemical and molecular products.

The global in-vitro diagnostic market is mature and the concentration rate is high. Top 5 manufacturers of global in-vitro diagnostic industry are Roche, Siemens, JNJ, Abbott and Beckman with an aggregate market share of over 60% in the globe as monopolies.

The market size of in-vitro diagnostics is closely related to the population base, medical treatment expenses per capita, medical care level and medical technology together with service levels of a country. At present, the demand market of global in-vitro diagnostics is mainly distributed in developed economies such as North America, Europe and Japan.

In China, major consumption demand for in-vitro diagnostic reagents derives from medical testing and blood screening. Medical testing is the major consumer of in-vitro diagnostic reagents including hospital clinical laboratory, physical examination center, independent laboratory and epidemic prevention station. Meanwhile, blood screening is mainly applied in blood collection and supply departments including various blood stations and blood product manufacturers. Presently, hospitals are major demand markets of in-vitro diagnostic reagents in China.

China's population accounts for more than 20% of the world, while the market share of in-vitro diagnostics is less than 10%. In 2016, the annual consumption per capita of China's in-vitro diagnostic products was less than USD 3, while that of developed countries reached USD 25 to USD 30. Therefore, there is a wide increase space for China's in-vitro diagnostic market. It is estimated that from 2017 to 2021, the market scale of China's in-vitro diagnostic market will develop at a growth rate exceeding that of the average global level to about CNY 49 billion with the CAGR of over 10%. Meanwhile, major shares will be occupied by immune and biochemical products, and molecular products will grow with a higher proportion.

Key Topics Covered:

1 Basic Concepts of In-vitro Diagnostic Reagent Industry
1.1 Definition of In-vitro Diagnostic Reagents
1.2 Classification of In-vitro Diagnostic Reagents
1.3 Industry Chain of In-vitro Diagnostic Reagents
1.4 Research Methods of the Report

2 Analysis on Global In-vitro Diagnostic Industry, 2011-2016
2.1 Overview on Global In-vitro Diagnostic Reagent Industry
2.2 Analysis on Major Global Manufacturers of In-vitro Diagnostic Reagents

3 Development Environment of China In-vitro Diagnostic Reagent Industry, 2011-2016
3.1 Economic Environment of In-vitro Diagnostic Reagent Industry
3.2 Policy Environment of In-vitro Diagnostic Reagent Industry

4 Operation Status of China Diagnostic Reagent Industry, 2011-2016
4.1 Development History of China In-vitro Diagnostic Reagent Industry
4.2 Supply Status of China In-vitro Diagnostic Reagent Industry
4.2.1 Major Manufacturers of China In-vitro Diagnostic Reagents
4.2.2 Supply Ability of China In-vitro Diagnostic Reagents
4.3 Market Demand for China In-vitro Diagnostic Reagents, 2011-2016
4.4 Analysis on Import and Export of In-vitro Diagnostic Reagents in China
4.5 Price Trend of Raw Materials of China In-vitro Diagnostic Reagents in China
4.5 Price Trend of In-vitro Diagnostic Reagents in China

5 Analysis on Competition in China In-vitro Diagnostic Reagent Industry, 2011-2016
5.1 Barriers to Entry in China In-vitro Diagnostic Reagent Industry
5.2 Competition Structure of China In-vitro Diagnostic Reagent Industry

6 Analysis on Major Manufacturers of In-vitro Diagnostic Reagents in China, 2013-2016
6.1 Shanghai Kehua Bio-engineering Co., Ltd.
6.2 Shenzhen Mindray Bio-medical Electronics Co., Ltd.
6.3 Sichuan Maccura Biotechnology Co., Ltd.
6.4 Shanghai Fosun Pharmaceutical Co., Ltd.
6.5 DAAN Gene Co., Ltd. of Sun Yat-sen University
6.6 Beijing Leadman Biochemistry Co., Ltd.
6.7 BioSino Bio-technology and Science Inc.

7 Prospect of China In-vitro Diagnostic Reagent Industry, 2017-2021
7.1 Factors Influencing the Development of In-vitro Diagnostic Reagent Industry in China
7.2 Forecast on Supply of China In-vitro Diagnostic Reagent Industry, 2017-2021
7.3 Forecast on Demand of China In-vitro Diagnostic Reagent Industry, 2017-2021
7.4 Forecast on Market Competition of In-vitro Diagnostic Reagent Industry in China

Companies Mentioned

- Abbott Laboratories
- Beckman Coulter
- Beijing Leadman Biochemistry Co., Ltd.
- BioSino Bio-technology and Science Inc.
- DAAN Gene Co., Ltd. of Sun Yat-sen University
- F. Hoffmann-La Roche Ltd
- JNJ
- Shanghai Fosun Pharmaceutical Co., Ltd.
- Shanghai Kehua Bio-engineering Co., Ltd.
- Shenzhen Mindray Bio-medical Electronics Co., Ltd.
- Sichuan Maccura Biotechnology Co., Ltd.
- Siemens AG

For more information about this report visit http://www.researchandmarkets.com/research/hqfjw2/research_report

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

© 2017 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.